The renin-angiotensin system (RAS) is a critical regulator of cardiovascular homeostasis, with its classical arm involving renin and angiotensin-converting enzyme (ACE) generating angiotensin II (Ang II), which activates the AT1 receptor, increasing blood pressure and inducing cardiovascular damage. However, Ang II also activates the AT2 receptor, which has opposing effects. Additionally, ACE2 converts Ang II into angiotensin-(1-7), which activates the Mas receptor, and its metabolite alamandine activates the MrgD receptor. These pathways, collectively termed the "alternative" or "protective" RAS, counteract the harmful effects of the classical RAS. The AT2 receptor, first identified in the 1980s, has been shown to have diverse physiological effects, including vasodilation, anti-inflammatory, and anti-proliferative actions. The Mas receptor, identified in the early 2000s, is a key receptor for angiotensin-(1-7), which has protective effects in various diseases. Alamandine, a derivative of angiotensin-(1-7), also activates MrgD and has similar protective effects. ACE2, a key enzyme in the RAS, is involved in the metabolism of various peptides and is essential for amino acid transport in the gut. ACE2 deficiency has been linked to various diseases, including hypertension and cardiovascular disorders. The alternative RAS has become a focus of therapeutic research, with several clinical trials exploring its potential in treating hypertension, heart failure, and other diseases. The study highlights the importance of the alternative RAS in maintaining cardiovascular homeostasis and its potential as a therapeutic target.The renin-angiotensin system (RAS) is a critical regulator of cardiovascular homeostasis, with its classical arm involving renin and angiotensin-converting enzyme (ACE) generating angiotensin II (Ang II), which activates the AT1 receptor, increasing blood pressure and inducing cardiovascular damage. However, Ang II also activates the AT2 receptor, which has opposing effects. Additionally, ACE2 converts Ang II into angiotensin-(1-7), which activates the Mas receptor, and its metabolite alamandine activates the MrgD receptor. These pathways, collectively termed the "alternative" or "protective" RAS, counteract the harmful effects of the classical RAS. The AT2 receptor, first identified in the 1980s, has been shown to have diverse physiological effects, including vasodilation, anti-inflammatory, and anti-proliferative actions. The Mas receptor, identified in the early 2000s, is a key receptor for angiotensin-(1-7), which has protective effects in various diseases. Alamandine, a derivative of angiotensin-(1-7), also activates MrgD and has similar protective effects. ACE2, a key enzyme in the RAS, is involved in the metabolism of various peptides and is essential for amino acid transport in the gut. ACE2 deficiency has been linked to various diseases, including hypertension and cardiovascular disorders. The alternative RAS has become a focus of therapeutic research, with several clinical trials exploring its potential in treating hypertension, heart failure, and other diseases. The study highlights the importance of the alternative RAS in maintaining cardiovascular homeostasis and its potential as a therapeutic target.